PTC Therapeutics (PTCT) shares surged 11.2% to $49.29 in the last trading session, driven by FDA approval of Sephience for treating PKU. The stock’s recent uptrend is supported by strong efficacy data. Analysts predict a quarterly loss of $1.06 per share with revenues of $170.66 million, signaling potential growth for the company.

Prothena’s stock rose 0.9% to $6.93, with an EPS estimate of -$1.11 for the upcoming report. The company holds a Zacks Rank of #3 (Hold) and operates in the same industry as PTCT. The data center market is booming, creating opportunities for semiconductor companies like PTCT and Prothena to capitalize on this growth.

Read more at Nasdaq: PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?